Skip to main content
Fig. 3 | Journal of Biological Engineering

Fig. 3

From: Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model

Fig. 3

Effect of a classic prophylactic vaccination with rBV on EG7-OVA cells in mice. a Experimental dosing was used to assess the antitumor immunity conferred by rBV. B6 mice were immunized with a single intramuscular injection of FrC-OVA-pVAX1-CAG-MCS (100 μg), wtBV (1 × 108 pfu), rBV (1 × 108 pfu) or PBS. At 14 and 35 days, EG7-OVA cells (5 × 106 cells/animal) were administered subcutaneously to the immunized mice. b The tumor volumes were measured every 2 days for 3 weeks. c Characterization of the established EG7-OVA tumor. Similar results were obtained in two independent experiments with 6 mice per group. The data are presented as the mean ± SD. *P < 0.05

Back to article page